EGFR and neoplasm: STK11 mutation presented accompanying with TP53 mutation in an EGFR T790M‐positive patient, which had been reported as a mediator of the cold tumor immune microenvironment and a major driver of primary resistance to PD‐1 axis inhibitors in nonsquamous lung adenocarcinoma.24